<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007047.ref031">
 <label>31</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Mavoko</surname>
   <given-names>HM</given-names>
  </name>, 
  <name>
   <surname>Nabasumba</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>da Luz</surname>
   <given-names>RI</given-names>
  </name>, 
  <name>
   <surname>Tinto</surname>
   <given-names>H</given-names>
  </name>, 
  <name>
   <surname>D’Alessandro</surname>
   <given-names>U</given-names>
  </name>, 
  <name>
   <surname>Kambugu</surname>
   <given-names>A</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial</article-title>. 
  <source>Lancet Glob Health</source>. 
  <year>2017</year>;
  <volume>5</volume>: 
  <fpage>e60</fpage>–
  <lpage>e68</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S2214-109X(16)30236-4</pub-id>
  <?supplied-pmid 27840069?>
  <pub-id pub-id-type="pmid">27840069</pub-id>
 </mixed-citation>
</ref>
